BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 34554237)

  • 1. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
    Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Fang C; Wang W; Feng X; Sun J; Zhang Y; Zeng Y; Wang J; Chen H; Cai M; Lin J; Chen M; Chen Y; Li Y; Li S; Chen J; Zhou Z
    Br J Cancer; 2017 Nov; 117(10):1544-1550. PubMed ID: 28949958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Xie S; Li L; Wang X; Li L
    Medicine (Baltimore); 2021 Jan; 100(2):e24223. PubMed ID: 33466202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study.
    Li X; Fan Y; Tong J; Lou M
    Front Endocrinol (Lausanne); 2024; 15():1264952. PubMed ID: 38449852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis.
    Li J; Lin Y; Wang Y; Lin H; Lin F; Zhuang Q; Lin X; Wu J
    ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32253246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.
    Gudmundsdottir H; Möller PH; Jonasson JG; Björnsson ES
    Scand J Gastroenterol; 2019 Jan; 54(1):69-75. PubMed ID: 30638086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database.
    Zhang Z; Zhao X; Li Z; Wu Y; Liu Y; Li Z; Li G
    BMC Cancer; 2021 May; 21(1):567. PubMed ID: 34006241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomogram predicting overall survival of rectal squamous cell carcinomas patients based on the SEER database: A population-based STROBE cohort study.
    Diao JD; Wu CJ; Cui HX; Bu MW; Yue D; Wang X; Liu YL; Yang YJ
    Medicine (Baltimore); 2019 Nov; 98(46):e17916. PubMed ID: 31725640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study.
    Xu G; Xiao Y; Hu H; Jin B; Wu X; Wan X; Zheng Y; Xu H; Lu X; Sang X; Ge P; Mao Y; Cai J; Zhao H; Du S
    Neuroendocrinology; 2022; 112(3):263-275. PubMed ID: 33902058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
    Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
    Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
    BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
    Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
    World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
    Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.